entertainment -WSS

entertainment

author：fashion 2025-10-01 15:39:31 - browse：1

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Morphosys mixed study results for blood cancer drug

leisure time

WSS

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

3 protesters arrested at Wimbledon after interrupting matches by throwing confetti on court

Pope Francis asks Church to identify 21st

David Sabatini, ex

Former New York Mayor de Blasio and wife announce separation, but not divorce

Astellas still sees hope in its gene therapy after four deaths

knowledge

entertainment

explore

Affirmative action in medical school literally saved lives

3 protesters arrested at Wimbledon after interrupting matches by throwing confetti on court

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

Virginia high school admissions case could be legal follow

China dismisses criticism of top diplomat's comments appearing to push for race

Walensky prepares to leave CDC — and Congress — behind

A daunting task: navigating dual Medicare, Medicaid eligibility

Novavax promises a turnaround & Lilly roils the obesity market

Poor hospice wound care hurts patients and families

leisure time

World's first CRISPR

3 protesters arrested at Wimbledon after interrupting matches by throwing confetti on court

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Ransomware attacks on hospitals: Study outlines patient impact

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Pentagon will tighten controls on classified information after Discord leak

leisure time

focus

focus

knowledge